10-K: Intra-Cellular Therapies, Inc. Details Share Structure and Corporate Governance in 10-K Filing

Intra-Cellular Therapies, Inc. outlines its common stock structure, anti-takeover provisions, and corporate governance policies in its latest 10-K filing.

Summary

• Intra-Cellular Therapies, Inc. has 175,000,000 authorized shares of common stock and 5,000,000 authorized shares of preferred stock, both with a par value of $0.0001 per share.
• Common stockholders are entitled to one vote per share and do not have cumulative voting rights.
• The company's board of directors is divided into three classes, with directors serving three-year terms.
• The company is subject to Delaware anti-takeover provisions, which could make it more difficult to change management or acquire control.
• Stockholder actions require a supermajority vote of 80% to amend certain provisions of the certificate of incorporation or bylaws.
• The company's common stock is listed on the Nasdaq Global Select Market under the symbol ITCI.
• The company's transfer agent and registrar is Computershare Trust Company, N.A.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment, providing factual information about the company's share structure and governance. It does not contain any particularly positive or negative news, but the anti-takeover provisions could be seen as slightly negative from a shareholder perspective.

Positives

• The company has a clear structure for its common stock and voting rights.
• The classified board of directors provides stability and continuity.
• The company is listed on a major stock exchange, providing liquidity for investors.

Negatives

• Anti-takeover provisions could deter transactions that stockholders may consider beneficial.
• The supermajority vote requirement for certain actions could make it difficult for stockholders to effect changes.
• The classified board structure may increase the time required for stockholders to change the board's composition.

Risks

• Anti-takeover provisions could discourage potential acquisitions or changes in management.
• The supermajority voting requirement could make it difficult for stockholders to amend the certificate of incorporation or bylaws.
• The classified board structure could make it more difficult for stockholders to change the composition of the board of directors quickly.
• The company is subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which could limit business combinations with interested stockholders for three years.

Industry Context

The document details standard corporate governance practices and share structure information common in publicly traded companies, particularly those incorporated in Delaware. The anti-takeover provisions are typical for companies seeking to maintain stability and control.

Comparison to Industry Standards

• The share structure with authorized common and preferred stock is standard for publicly traded companies.
• The classified board structure is a common practice to ensure board continuity, although it can be seen as less shareholder-friendly than a fully declassified board.
• The anti-takeover provisions, including the supermajority vote requirement, are similar to those found in many Delaware-incorporated companies, designed to protect against hostile takeovers.
• The listing on the Nasdaq Global Select Market is a common venue for biotechnology companies.

Corporate Governance

Stakeholder Impact

• Shareholders may find it more difficult to influence company decisions due to the supermajority voting requirements and classified board.
• Potential acquirers may be deterred by the anti-takeover provisions.
• Management is provided with greater stability and protection from hostile takeovers.

Keywords

common stock, corporate governance, anti-takeover provisions, board of directors, Delaware law, stockholders, Nasdaq, voting rights, bylaws, certificate of incorporation